Search for: "Celgene Corporation" Results 21 - 40 of 49
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
12 Oct 2015, 12:46 pm by Gene Quinn
The first bit of good news for Bass came with respect to his IPR petition against Celgene Corporation. [read post]
12 Oct 2015, 12:46 pm by Gene Quinn
The first bit of good news for Bass came with respect to his IPR petition against Celgene Corporation. [read post]
3 Jun 2015, 1:40 pm by Tom Lamb
  In more detail, from the Celgene Corporation Prescribing information for Pomalyst (accessed 6/3/15): POMALYST, in combination with dexamethasone, is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy. [read post]
31 Jul 2014, 6:43 am by Pete Strom
Qui-Tam Lawsuit Against Celgene for Off-Label Marketing of Drugs Will Proceed A qui-tam lawsuit brought against Celgene Corporation for two of its cancer drugs will proceed, according to a judge that refused to throw the lawsuit out. [read post]
21 Apr 2014, 5:52 am
("Andrulis") filed a patent infringement action against Celgene Corporation ("Celgene") alleging direct, induced, and contributory infringement. [read post]
12 Jun 2013, 10:16 am by Barry Sookman
On those findings, it is clear that the substance of the sale transaction takes place through RXP, an Ontario corporation that is located and operates in Ontario. [read post]
30 Jun 2012, 11:02 pm by Mark Summerfield
We recently reported the Australian Patent Office decision in Celgene Corporation [2012] APO 71, relating to a system for dispensing drugs with significant safety issues (such as thalidomide). [read post]
30 Jun 2012, 9:56 pm by Mark Summerfield
Celgene Corporation [2012] APO 71 (25 June 2012) Manner of Manufacture – whether a system for dispensing a drug which provides a ‘prescription approval’ is patent-eligible Back in January, we reported a decision of the Australian Patent Office in which patent claims from Celgene corporation, relating to a method of dispensing drugs with significant safety issues (such as thalidomide), were rejected as being directed to an unpatentable… [read post]
19 May 2012, 10:25 am
The plaintiff, David Schmidt, alleged retaliation after he blew the whistle against his employer, Celgene Corporation, and CVS/Caremark Corporation, one of Celgene’s distributors. [read post]
27 Jan 2012, 5:00 am by Stephen Jenei
Thompson did not disclose that Agios was going to sell to Celgene Corporation an exclusive option to develop any drugs resulting from the cancer metabolism research platform. [read post]
25 Jan 2012, 10:01 pm by Mark Summerfield
Celgene Corporation [2012] APO 12 (17 January 2012) Manner of Manufacture – whether a method of dispensing a drug with a ‘prescription approval’ step is patent-eligible – novelty – whether use of a ‘prescription approval code’ makes method new We wrote back in June last year about Celgene Corporation’s unsuccessful application for an extension of term of a patent for the drug REVLIMID the active ingredient of which… [read post]
24 Jan 2012, 3:00 am by LindaMBeale
   Back before Nixon, corporate tax returns were public information and were not kept secret by the Service. [read post]
6 Jun 2011, 11:51 am by Christine Hurt
  Anyway, the article highlights shareholders at Celgene Corporation who have found each other on the Internet and are trying to gather enough folks together to vote down the executive compensation pay package at the upcoming annual meeting. [read post]
28 Oct 2010, 10:14 am by FDABlog HPM
  Consider, for example, a recent quarterly report from Celgene Corporation, which states with respect to Risk Evaluation and Mitigation Strategies (“REMS”) that: In the fourth quarter of 2009, we received a civil inquiry and demand from the [Federal Trade Commission (“FTC”)]. [read post]
30 Jun 2010, 3:36 am by By DEALBOOK
Celgene Corporation, the biopharmaceutical company, said Wednesday that it would buy Abraxis BioScience in a cash and stock deal that values the company at $2.9 billion. [read post]
21 Jun 2010, 7:29 am by Theo Francis
Image source: mijita via Flickr ———— Want to see more of what’s hidden in corporate filings? [read post]
1 Dec 2009, 9:39 am
The company has a practice of using a multitude of corporate names and billing addresses for work by its subsidiaries, creating confusion for Howrey as to who its client really was in a related European case. [read post]
27 Aug 2009, 3:22 pm
Jacobson has now brought a lawsuit against the Celgene Corporation (Jacobson v. [read post]